Orphan drug designation is granted by the FDA Office of Orphan Products Development to promote the development of investigational therapies for diseases affecting less than 200,000 people in the US.
Benefits that come with an orphan drug designation include, but not limited to, tax credits for clinical development cost and seven-year market exclusivity.
Netherton Syndrome is a severe autosomal recessive disease characterized by congenital erythroderma, "bamboo hair" and abnormality in the immune system.
It can be life-threatening in pediatrics due to impaired skin barrier that leads to severe dehydration, hypernatremia, hypothermia, gross weight loss and sepsis.
Failure to thrive is common in childhood as a result of chronic erythroderma, persistent cutaneous infection, malnutrition and metabolic disorders. The severity of the skin abnormality in older patients can fluctuate over time.
Most Netherton Syndrome patients are also inflicted with immune system-related disorders such as food allergies and asthma.
Though the exact prevalence of Netherton Syndrome is not well documented, it has a reported prevalence of 1-9 per 1,000,000.
LifeMax Laboratories, Inc., a wholly-owned subsidiary of LifeMax Healthcare International Corp., is a clinical-stage biotech company focused on treating rare diseases with few or no therapeutic options.
LifeMax is applying its expertise and in-depth experience with drug development and commercialization to advance its well-balanced portfolio of products addressing critical unmet medical needs.
Inimmune signs research collaboration with Boston Children's Hospital
ResVita Bio receives USD250,000 phase one Small Business Innovation Research grant from NIAID
Phase II Data of Oral Dexpramipexole Published in Eosinophilic Asthma
AllerVie Health Rebrands Southern Allergy & Asthma
Applied BioCode Inks Distribution Agreement with Medline Industries
Vedanta Biosciences Receives Fast Track Designation for VE303
KalVista Pharmaceuticals Presents Data at 13th C1-inhibitor Deficiency & Angioedema Workshop
French Ophthalmology Specialist Horus Pharma Group Launches a Nordic Subsidiary